How much funding has Epitome Therapeutics raised?

Epitome Therapeutics has raised $6.6M in total funding, most recently a Pre-Seed round.

When was Epitome Therapeutics founded?

Epitome Therapeutics was founded in 2025.

Where is Epitome Therapeutics headquartered?

Epitome Therapeutics is headquartered in Vienna, Austria.

What industry is Epitome Therapeutics in?

Epitome Therapeutics operates in Biotech, Healthcare.

How many employees does Epitome Therapeutics have?

Epitome Therapeutics has 1-10 employees.

Epitome Therapeutics

Vienna, Austria · Founded 2025 · $6.6M raised

Biotech

Healthcare

Headquarters: Vienna
Employees: 1–10
Founded: 2025
Business Model: B2B

Website: epitome-tx.com
Total Funding: $6.6M
Last Round: $4.4M Pre-SeedJun 2026
Rounds: 2

About

Epitome Therapeutics is a Vienna-based biotechnology company developing a proprietary epigenome editing platform called CADENCE, designed to achieve precise, durable activation of gene expression without altering DNA sequence. Founded in 2025 as a spin-off from the European Molecular Biology Laboratory (EMBL) in Rome by co-founders Dr. Guido Gualdoni (CEO) and Dr. Jamie Hackett (CSO), the company focuses on diseases requiring restoration or fine-tuning of gene activity. Epitome raised €4M in total pre-seed financing co-led by XISTA Science Ventures and Caesar Ventures to advance its first drug candidate selection.

Summary

Epitome Therapeutics is a Biotech company based in Vienna, Austria, founded in 2025. It has raised $6.6M in total across 2 rounds, most recently a $4.4M Pre-Seed round in Jun 2026.